Cannabinoids and the Gastrointestinal Tract

被引:10
作者
Camilleri, Michael [1 ,2 ]
Zheng, Ting [1 ]
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, Clin Enter Neurosci Translat & Epidemiol Res, Rochester, MN 55905 USA
[2] Mayo Clin, 200 First St SW,Charlton Bldg,Room 8-110, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
Cannabis; Gastroparesis; Inflammatory Bowel eases; Nausea; Vomiting; Pain Disorders; INFLAMMATORY-BOWEL-DISEASE; CHRONIC NEUROPATHIC PAIN; ENDOCANNABINOID SYSTEM; CROHNS-DISEASE; DOUBLE-BLIND; RECEPTORS; CANNABIDIOL; HYPEREMESIS; AGONIST; CONTRACTILITY;
D O I
10.1016/j.cgh.2023.07.031
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The synthesis and degradation of endocannabinoids, location of cannabinoid (CB) receptors, and cannabinoid mechanisms of action on immune/inflammatory, neuromuscular, and sensory functions in digestive organs are well documented. CB2 mechanisms are particularly relevant in immune and sensory functions. Increasing use of cannabinoids in the United States is impacted by social determinants of health including racial discrimination, which is associated with tobacco and cannabis co-use, and combined use disorders. Several conditions associated with emesis are related to cannabinoid use, including cannabinoid hyperemesis or withdrawal, cyclic vomiting syndrome, and nausea and vomiting of pregnancy. Cannabinoids generally inhibit gastrointestinal motor function; yet they relieve symptoms in patients with gastroparesis and diverse nausea syndromes. Cannabinoid effects on inflammatory mechanisms have shown promise in relatively small placebo-controlled studies in reducing disease activity and abdominal pain in patients with inflammatory bowel disease. Cannabinoids have been studied in disorders of motility, pain, and disorders of gut-brain interaction. The CB2-receptor agonist, cannabidiol, reduced the total Gastroparesis Cardinal Symptom Index and increases the ability to tolerate a meal in patients with gastroparesis appraised over 4 weeks of treatment. In contrast, predominant-pain end points in functional dyspepsia with normal gastric emptying were not improved significantly with cannabidiol. The CB2 agonist, olorinab, reduced abdominal pain in inflammatory bowel disease in an openlabel trial and in constipation-predominant irritable bowel syndrome in a placebo-controlled trial. Cannabinoid mechanisms alter inflammation in pancreatic and liver diseases. In conclusion, cannabinoids, particularly agents affecting CB2 mechanisms, have potential for inflammatory, gastroparesis, and pain disorders; however, the trials require replication and further understanding of riskdiseases.
引用
收藏
页码:3217 / 3229
页数:13
相关论文
共 123 条
[1]   Reduced Risk of Alcohol-Induced Pancreatitis With Cannabis Use [J].
Adejumo, Adeyinka Charles ;
Akanbi, Olalekan ;
Adejumo, Kelechi Lauretta ;
Bukong, Terence Ndonyi .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2019, 43 (02) :277-286
[2]   Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse [J].
Allen, JH ;
de Moore, GM ;
Heddle, R ;
Twartz, JC .
GUT, 2004, 53 (11) :1566-1570
[3]   Cannabis, Cannabinoids, and the Endocannabinoid SystemIs there Therapeutic Potential for Inflammatory Bowel Disease? [J].
Ambrose, Tim ;
Simmons, Alison .
JOURNAL OF CROHNS & COLITIS, 2019, 13 (04) :525-535
[4]   Cannabinoid hyperemesis syndrome in North America: evaluation of health burden and treatment prevalence [J].
Andrews, Christopher N. ;
Rehak, Renata ;
Woo, Matthew ;
Walker, Ian ;
Ma, Christopher ;
Forbes, Nauzer ;
Rittenbach, Katherine ;
Hathaway, Joshua ;
Wilsack, Lynn ;
Liu, Andy ;
Nasser, Yasmin ;
Sharkey, Keith A. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (11-12) :1532-1542
[5]   Hepatocyte-stellate cell synapse in alcohol-induced steatosis: another role for endocannabinoids [J].
Argemi, Josepmaria ;
Bataller, Ramon .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2020, 17 (01) :5-6
[6]   Cannabidiol for Functional Dyspepsia With Normal Gastric Emptying: A Randomized Controlled Trial [J].
Atieh, Jessica ;
Maselli, Daniel ;
Breen-Lyles, Margaret ;
Torres, Monique ;
Katzka, David ;
Ryks, Michael ;
Busciglio, Irene ;
Burton, Duane ;
Carlson, Paula ;
Harmsen, W. Scott ;
Camilleri, Michael .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (08) :1296-1304
[7]  
Ayisire OE, 2022, Cureus, V14
[8]   Cannabinoid-Related Acute Pancreatitis: An Update from International Literature and Individual Case Safety Reports [J].
Azam, Camille ;
Buscail, Louis ;
Culetto, Adrian ;
Lapeyre-Mestre, Maryse .
DRUG SAFETY, 2022, 45 (03) :215-235
[9]   Epidemiology, Clinical Characteristics, and Associations for Rome IV Functional Nausea and Vomiting Disorders in Adults [J].
Aziz, Imran ;
Palsson, Olafur S. ;
Whitehead, William E. ;
Sperber, Ami D. ;
Simren, Magnus ;
Tornblom, Hans .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (05) :878-886
[10]   Impact of Cannabinoids on Symptoms of Refractory Gastroparesis: A Single-center Experience [J].
Barbash, Benjamin ;
Mehta, Dhruv ;
Siddiqui, Mohamed Tausif ;
Chawla, Lavneet ;
Dworkin, Brad .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (12)